To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregat...

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregat...

Background. — The salt linked to the clopidogrel molecule in generic preparations is suspected to affect its clinical efficacy. There is a lack of information about inhibition of platelet reactivity by generic preparations. Aims. — To compare the effect of original clopidogrel (clopidogrel bisulphate [Plavix®]), generic clopidogrel preparations (clopidogrel hydrochloride [Clopidogrel-Mepha®]; c...

Clopidogrel pharmacotherapy is associated with substantial interindividual variability in clinical response, which can translate into an increased risk of adverse outcomes. Clopidogrel, a recognized substrate of hepatic carboxylesterase 1 (CES1), undergoes extensive hydrolytic metabolism in the liver. Significant interindividual variability in the expression and activity of CES1 exists, which i...

• Clopidogrel decreases platelet activation (sCD40L levels, CD40L, P-selectin, MPV) in SLE patients. appears to have a suspensive effect on The use of clopidogrel is safe and well-tolerated patients, with no treatment-related mortality.

Clopidogrel is an effective and specific inhibitor of ADP-induced platelet aggregation. After metabolic activation, the active clopidogrel metabolite irreversibly impairs the human platelet P2Y12 ADP receptor. Gialpha-protein activation and inhibition of vasodilator-stimulated phosphoprotein (VASP) phosphorylation are two key elements of the P2Y12 receptor pathway suitable for quantitation of c...

The prodrug clopidogrel (Plavix) is activated by cytochrome p450 (p450) to a metabolite that inhibits ADP-induced platelet aggregation. Clopidogrel is frequently administered to patients in conjunction with the CYP3A4 substrate atorvastatin (Lipitor). Since clinical studies indicate that atorvastatin inhibits the antiplatelet activity of clopidogrel, we investigated whether CYP3A4 metabolized c...

clopidogrel, an inhibitor of platelet aggregation, selectively inhibits the binding of adenosine diphosphate (adp) to its platelet receptor and the subsequent adp-mediated activation of the glycoprotein gpiib/iiia complex, thereby inhibiting platelet aggregation. oral bioavailability of clopidogrel is very low (less than 50%), due to its poor water solubility. the aim of this investigation was ...

conclusions we found that the use of clopidogrel in patients undergoing pci had favorable effects on the suppression of hs-crp. this effect appears to be heightened and more apparent in some group of patients with co-morbidities such as diabetes and hypertension. results six hundred-fifty patients including 386 (59.4%) male and 264 (40.6%) female subjects were enrolled in the study. the mean hs...